Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Q1 2022 Earnings Conference Call May 4, 2022 4:30 PM ET
Company Participants
Karina Calzadilla - Vice President of Investor Relations
Chad Robins - Chief Executive Officer and Co-Founder
Kyle Piskel - Interim Chief Financial Officer
Sharon Benzeno - Chief Commercial Officer, Immune Medicine
Nitin Sood - Chief Commercial Officer, MRD
Harlan Robins - Chief Scientific Officer
Conference Call Participants
Brian Weinstein - William Blair
Elizabeth Webster - Goldman Sachs
Mark Massaro - BTIG
Yuko Oku - Morgan Stanley
Derik de Bruin - Bank of America
Disclaimer*: This transcript is designed to be used alongside the freely available audio recording on this page. Timestamps within the transcript are designed to help you navigate the audio should the corresponding text be unclear. The machine-assisted output provided is partly edited and is designed as a guide.
Operator
00:03 Ladies and gentlemen, thank you for standing by. And welcome to the Adaptive Biotechnologies First Quarter 2022 Financial Results Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session. [Operator Instructions]
00:30 I would now like to hand the conference over to your speaker today Karina Calzadilla, Head of Investor Relations. Please go ahead ma'am.
Karina Calzadilla
00:40 Thank you, Alexandra, and good afternoon everyone. I would like to welcome you to Adaptive Biotechnologies first quarter 2022 earnings conference call. Earlier today, we issued a press release reporting Adaptive financial results for the first quarter of 2022.
00:54 The press release is available at www.adaptivebiotech.com. We are conducting a live webcast of this call and will be referencing to a slide presentation that has been posted to the Investors section in our corporate website.
01:07 During the call, management will make projections and other forward-looking statements within the meaning of federal securities laws regarding future events and the future financial performance of the company. These statements reflect management's current perspective of the business as of today. Actual results may differ materially from today's forward-looking statements, depending on a number of factors, which are set forth in our public filings with the SEC and listed in this presentation.
01:33 Joining the call today are Chad Robins, our CEO and Co-Founder; and Kyle Piskel, our Interim Chief Financial Officer. In addition, Harlan Robins, Adaptive's Chief Scientific Officer and Co-Founder; Nitin Sood, our Head of our MRD business, and Sharon Benzeno, Head of the Immune Medicine business will be available for Q&A.